Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT1NW2)

Drug Name

8(S)-amino-2(R)-methyl-7-oxononanoic acid Drug Info

Synonyms

8(S)-Amino-2(R)-methyl-7-oxononanoic acid; CHEMBL465576; Nonanoic acid, 8-amino-2-methyl-7-oxo-, (S-(R*,S*))-; 181886-81-7; SCHEMBL4098289; AC1L42P6; DTXSID90171213; BDBM50292361; (2R,8S)-8-amino-2-methyl-7-oxononanoic acid; (2R,8S)-2-Methyl-7-oxo-8-aminononanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 177363
CAS Number: CAS 181886-81-7
TTD Drug ID: DMT1NW2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukotriene A-4 hydrolase (LTA4H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bestatin	DM8L9D4	Acute myeloid leukaemia	2A60	Approved	[2]
LYS006	DMI17QR	Ulcerative colitis	DD71	Phase 2	[3]
Acebilustat	DM19UTO	Chronic blistering skin disorder	ME63.3	Phase 1	[4]
DG051	DM3I0GS	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[5]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[6]
JNJ-10392980	DMZH0K8	Discovery agent	N.A.	Investigative	[7]
4-(2-amino-1,3-thiazol-4-yl)phenol	DMH5CAQ	Discovery agent	N.A.	Investigative	[8]
2-(4-phenoxyphenoxy)ethanamine	DM7TBUJ	Discovery agent	N.A.	Investigative	[9]
3-(Benzyloxy)Pyridin-2-Amine	DM35VEI	Discovery agent	N.A.	Investigative	[6]
2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine	DMD2QVO	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukotriene A-4 hydrolase (LTA4H)	TTXZEAJ	LKHA4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Isolation and structure of leukotriene-A4 hydrolase inhibitor: 8(S)-amino-2(R)-methyl-7-oxononanoic acid produced by Streptomyces diastaticus. J Nat Prod. 1996 Oct;59(10):962-4.
2	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
3	Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A(4) Hydrolase. J Med Chem. 2021 Feb 25;64(4):1889-1903.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
6	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7	Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69.
8	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9	Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52.
10	Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.